Ionis Pharmaceuticals, Inc. IONS NASDAQ

Ionis Pharmaceuticals, Inc. (IONS) generated $-268.58M in operating cash flow for fiscal year 2025. After capital expenditures of $51.44M, free cash flow was $-320.03M.

Free cash flow margin was -33.9% of revenue. Cash conversion ratio was 0.7x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (33/100, Fail) — weak cash flow raises concerns about debt servicing
• MOAT (72/100, Pass) — $-320.03M (-33.9% FCF margin) supports a durable competitive advantage
• INCOME (10/100) — Cash conversion ratio was 0.7x suggests some earnings are non-cash items

Overall SharesGrow Score: 46/100 with 3/7 criteria passed.